Authors' objectives: Multiple myeloma is a cancer which develops in the bone marrow from plasma cells (a type of white blood cell). Multiple myeloma is more common in men than women and also more common in older people. For most patients, multiple myeloma is not curable. Treatment is often successful at first but then it begins to stop working and the disease returns. Plitidepsin is a new drug being developed for the treatment of multiple myeloma that is delivered straight into the blood stream via a drip every two weeks. Some studies have suggested that plitidepsin may be helpful for people whose first three treatments have already failed and whose disease has spread. More studies are now aiming to show how well it works and whether it is safe to use.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/plitidepsin-aplidin-for-relapsed-and-refractory-multiple-myeloma-fourth-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)